Median and range |
67.5 (28–81) |
|
Sex (n = 24) |
|
|
Female |
7 |
29.2% |
Male |
17 |
70.8% |
Histology (n = 24) |
|
|
Prostate cancer |
11 |
45.8% |
Renal cell carcinoma |
3 |
12.6% |
Urothelial cancer |
2 |
8.3% |
Other* |
8 |
33.3% |
Localization of irradiated metastasis (n = 28) |
|
|
Spine |
20 |
71.4% |
Rib |
4 |
14.3% |
Other (sternum, femur 2x, sacral bone) |
4 |
14.3% |
Oligometastatic vs. diffuse metastatic disease (n = 24) |
|
|
Oligometastatic disease |
16 |
66.7% |
Diffuse metastatic disease |
8 |
33.3% |
Indication for radiation therapy (n = 24) |
|
|
Oligometastatic disease |
15 |
62.5% |
Oligoprogression under systemic therapy |
4 |
16.7% |
Radiation resistant histology |
3 |
12.5% |
Intraspinal tumour component |
2 |
8.3% |
Systemic therapy (n = 24) |
|
|
No systemic therapy |
4 |
16.7% |
Chemotherapy or immunotherapy |
10 |
41.7% |
Hormonal therapy |
10 |
41.7% |